Thursday, April 13, 2017
3:00pm – 4:30pm Eastern time
1.5 CE Credits
Eric Edward Smith, MD, MPH, FRCPC, FAHA
Associate Professor of Neurology
Katthy Taylor Chair in Vascular Dementia
Cumming School of Medicine, University of Calgary
Alzheimer's disease is well known as the commonest neuropathology of dementia. The hallmark of Alzheimer's disease is neuropathological accumulation of senile plaques and neurofibrillary tangles, leading to medial temporal atrophy and impairments in episodic memory that subsequently progress to global impairments. However, a decade of research has identified atypical presentations of Alzheimer's disease, marked by initial focal degeneration outside the medial temporal lobe and presenting with abnormalities in behavior, language, or visuospatial function. Additionally, it is now recognized that pure Alzheimer's disease is the exception, and Alzheimer's disease with one or more co-pathologies is the rule. These co-pathologies also alter the course and clinical presentation of Alzheimer's disease.
After the webinar, participants will be able to:
- Discuss the classification of atypical Alzheimer's disease.
- List diagnostic criteria for atypical Alzheimer's disease.
- Describe the clinical, cognitive, and behavioral features of atypical Alzheimer's disease.
- Describe the most common comorbid neuropathologies in Alzheimer's disease patients and their clinical features.
Target Audience: Clinical psychologists and neuropsychologists
NAN members login and non-members create an account to:
Instructional Level: Intermediate (Basic clinical knowledge of AD pathology and clinical neuropsychology is assumed)
Registration closes 30 minutes prior to the live presentation.
Eric Edward Smith, M.D.
is Associate Professor of Neurology, Radiology and Community Health Sciences at the University of Calgary, where he directs the Cognitive Neurosciences Clinic and is a member of the Calgary Stroke Program. He holds the endowed Katthy Taylor Chair in Vascular Dementia at the University of Calgary. Dr. Smith’s research uses neuroimaging to investigate the risk factors for, and consequences of, cerebral small vessel disease in healthy populations and in patients with mild cognitive impairment or cerebral amyloid angiopathy. He leads the Vascular Cognitive Impairment team of Canada’s national research strategy for dementia, the Canadian Consortium on Neurodegeneration in Aging.